Lupin’s Somerset plant received US FDA warning letter for
Lupin has received a warning letter from the US Food and Drug Administration relating to its US-based manufacturing plant located in Somerset,... Read More
What is Cytokine Storm?
Cytokine Storm is a severe immune reaction in which the body releases too many cytokines into the blood too quickly. Cytokines play... Read More
FDA Grants Accelerated Approval for Alzheimer’s drug Aduhelm
Posted on10 Jun 2021
Tagsaducanumab, Aduhelm, Biogen, Eisai, global pharma licensing deal, monoclonal antibody, Neurimmune, pharma deal
Comments0
USFDA approved Aduhelm (aducanumab) for the treatment of Alzheimer disease. Alzheimer’s drug Aduhelm is research molecule of Neurimmune. Neurimmune licensed its antibody... Read More
Insight on Neurogastrx licensing deal with Daewoong Pharmaceutical to Develop Fexuprazan
Neurogastrx, Inc. has entered into an exclusive license agreement with Daewoong Pharmaceutical Co., Ltd., of Seoul, South Korea, for the development and... Read More
Case study – Adagrasib out licensing deal
Posted on04 Jun 2021
Comments0
Zai Lab said on Tuesday it has entered into a license agreement with Mirati Therapeutics to develop and commercialize Mirati’s KRAS G12C inhibitor... Read More
CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China
CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (AFib), announced today that it has entered into... Read More
Cosentyx of Novartis Gets US FDA approval in Pediatric Plaque Psoriasis
The U.S. Food and Drug Administration (FDA) has approved Novartis’ blockbuster drug Cosentyx® (secukinumab) for pediatric patients aged six years and older with moderate-to-severe plaque psoriasis.... Read More
Lupin received US FDA biosimilar approval of pegfilgrastim
Global pharma major, Lupin Limited (Lupin) today announced that the U.S. FDA has accepted the Biologics License Application (BLA) for its proposed... Read More
Corbus Pharma in-licenses two integrin targeting MAbs
US biotech Corbus Pharmaceuticals (Nasdaq: CRBP) today announced the expansion of its portfolio into immuno-oncology through licensing deals for two new monoclonal... Read More
Case Study: Strategic Insight of acquisition of Constellation Pharmaceuticals by MorphoSys
Posted on03 Jun 2021
TagsConstellation Pharmaceuticals, MorphoSys AG, pharma deal, pharma strategic deal, strategic management in pharma
Comments0
MorphoSys AG, and Constellation Pharmaceuticals, Inc. announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00... Read More